Others Urological ConditionsArchives
The role of plant-derived compounds in the management and prevention of urolithiasis: a review of evidence and mechanisms
Others Urological Conditions 1 min.
Urolithiasis, the condition of forming stones in the urinary system, is a common health problem worldwide and tends to recur. Pathophysiology includes stages such as supersaturation, nucleation, growth, aggregation, and crystal-cell interactions. Most conventional treatments have disadvantages of failing...
Rapid and accurate preoperative diagnosis of urinary tract infections in urolithiasis patients: clinical validation of the HB&L system
Others Urological Conditions 6 min.
Urinary tract infections (UTIs) represent a significant clinical challenge in patients with urolithiasis [1], with infection rates reported between 7 and 28% of stone formers [2], increasing hospitalization duration and treatment costs substantially when complications arise. The management of these infections...
Comparing the clinical accuracy of urine exfoliated cell examination and fluorescence in situ hybridization in the diagnosis of upper urinary tract urothelial carcinoma
Others Urological Conditions 4 min.
Upper urinary tract urothelial carcinoma (UTUC), which refers to renal pelvis cancer and ureteral cancer, is a rare malignant tumor that comprises 5% to 10% of all urothelial tumors. Based on statistics, UTUC has an incidence of approximately 2/100,000, or 2 per 100,000 of the general population [1,...
Immune checkpoint inhibitors in urothelial carcinoma: a practical framework for patient selection, toxicity management, response assessment, and treatment sequencing
Others Urological Conditions 1 min.
Managing urothelial carcinoma with immune checkpoint inhibitors requires addressing issues beyond clinical outcomes. Implementation difficulties affect most patients, predictive biomarkers show limited utility, and treatment discontinuation from toxicity remains problematic. This article integrates clinical...
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
Others Urological Conditions 1 min.
Enfortumab vedotin (EV) plus pembrolizumab is the first-line standard of care for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). However, randomized data to guide treatment after progression on EV plus pembrolizumab are limited. Datopotamab deruxtecan (Dato-DXd), a trophoblast...
